Astrazeneca (AZN) closed the last trading session at $67.30, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $86.07 indicates a 27.9% upside potential.The mean estimate comprises 10 short-term price targets with a standard deviation of $10.38. While the lowest estimate of $67 indicates a 0.5% decline from the current price level, the most optimistic analyst expects the ...

Tempus AI TodayTEMTempus AI$58.76 +6.57 (+12.59%) 52-Week Range$22.89▼$91.45Price Target$61.08Add to WatchlistTempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance. The company’s results are a testament to its utility, growing at ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank put ...

AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - EVP, Oncology Business Unit Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Unit Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP, International Conference Call Participants Sarita Kapila - Morgan S ...

Astrazeneca (AZN) reported $13.59 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7.2%. EPS of $1.24 for the same period compares to $1.03 a year ago.The reported revenue represents a surprise of -0.66% over the Zacks Consensus Estimate of $13.68 billion. With the consensus EPS estimate being $1.10, the EPS surprise was +12.73%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

AstraZeneca’s (AZN) first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on a reported basis as well as at constant exchange rates (CER).Total revenues of $13.59 billion rose 7% on a reported basis and 10% at CER, driven by higher product sales and alliance revenues from partnered medicines. However, the metric missed the Zacks Consensus Estimate of $13.68 billion. (Find the latest E ...

BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions world ...

Core Viewpoint - Tempus AI has experienced a significant stock increase of 21% over three days, driven by a $200 million partnership with AstraZeneca and Pathos AI to develop an AI-driven foundation model for oncology [1][2][6] Group 1: Partnership and Financial Impact - The $200 million multi-year collaboration includes data licensing and model development fees, utilizing Tempus AI's de-identified oncology dataset [6] - This partnership is expected to match Tempus AI's fourth-quarter 2024 revenues, indicating a major milestone for the company [7] Group 2: Market Performance - In the last three days, Tempus AI's stock outperformed the Medical Info Systems industry (2.3%), the Medical sector (2%), and the S&P 500 (2.5%) [3] - Compared to other health infotech companies, Tempus AI has outperformed iRhythm Technologies (4.1%) and SOPHiA GENETICS (10.1%) during the same period [3] Group 3: Strategic Acquisitions and Innovations - Tempus AI's stock has risen nearly 47% in 2025, largely due to the acquisition of Deep 6 AI, enhancing its clinical trial matching capabilities [8] - The acquisition of Ambry Genetics has expanded Tempus AI's genomics capabilities, while a five-year extension with Google ensures cost-efficient cloud infrastructure [9] - The launch of the xT CDx in vitro diagnostic device and the Olivia health concierge app adds to Tempus AI's portfolio of diagnostic tools [10] Group 4: Valuation and Earnings Outlook - Tempus AI trades at a forward price-to-sales (P/S) ratio of 6.4, which is a premium compared to peers but below its one-year median of 8.31, suggesting cautious optimism [11] - EPS revisions have trended downward, with a projected loss of 58 cents per share for 2025, and rising operating costs may impact short-term earnings sentiment [12] Group 5: Long-term Positioning - The AstraZeneca deal positions Tempus AI as a foundational player in oncology, supported by strategic alliances and the CMS reimbursement approval for its ECG-AF algorithm [15] - Despite rising operational costs and a focus on long-term investments, the company has yet to report positive earnings, which may limit near-term gains [16]

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association bet ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]